Free Trial

Karyopharm Therapeutics (KPTI) Competitors

Karyopharm Therapeutics logo
$3.85 -0.22 (-5.41%)
Closing price 04:00 PM Eastern
Extended Trading
$4.02 +0.17 (+4.42%)
As of 06:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

KPTI vs. LIMN, INKT, TIL, CRBU, NXTC, IPHA, LFVN, IMRX, ENTA, and SPRO

Should you be buying Karyopharm Therapeutics stock or one of its competitors? The main competitors of Karyopharm Therapeutics include Liminatus Pharma (LIMN), MiNK Therapeutics (INKT), Instil Bio (TIL), Caribou Biosciences (CRBU), NextCure (NXTC), Innate Pharma (IPHA), Lifevantage (LFVN), Immuneering (IMRX), Enanta Pharmaceuticals (ENTA), and Spero Therapeutics (SPRO). These companies are all part of the "pharmaceutical products" industry.

Karyopharm Therapeutics vs. Its Competitors

Liminatus Pharma (NASDAQ:LIMN) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment and profitability.

66.4% of Karyopharm Therapeutics shares are held by institutional investors. 3.0% of Karyopharm Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Liminatus Pharma has higher earnings, but lower revenue than Karyopharm Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Liminatus PharmaN/AN/AN/AN/AN/A
Karyopharm Therapeutics$145.24M0.23-$76.42M-$13.26-0.29

Karyopharm Therapeutics has a consensus target price of $37.40, suggesting a potential upside of 871.43%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Karyopharm Therapeutics is more favorable than Liminatus Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Liminatus Pharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Karyopharm Therapeutics
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80

In the previous week, Karyopharm Therapeutics had 2 more articles in the media than Liminatus Pharma. MarketBeat recorded 3 mentions for Karyopharm Therapeutics and 1 mentions for Liminatus Pharma. Liminatus Pharma's average media sentiment score of 0.00 beat Karyopharm Therapeutics' score of -0.05 indicating that Liminatus Pharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Liminatus Pharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Karyopharm Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Liminatus Pharma has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -43.99%.

Company Net Margins Return on Equity Return on Assets
Liminatus PharmaN/A N/A N/A
Karyopharm Therapeutics -43.99%N/A -35.95%

Summary

Karyopharm Therapeutics beats Liminatus Pharma on 7 of the 10 factors compared between the two stocks.

Get Karyopharm Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KPTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KPTI vs. The Competition

MetricKaryopharm TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$35.16M$2.46B$5.54B$9.41B
Dividend YieldN/A1.80%3.75%4.03%
P/E Ratio-0.294.4521.0120.09
Price / Sales0.23709.89433.8199.01
Price / CashN/A164.7736.1658.27
Price / Book-0.175.008.125.65
Net Income-$76.42M$30.99M$3.25B$257.91M
7 Day Performance-15.38%1.69%0.97%2.09%
1 Month Performance-13.29%9.20%7.36%11.13%
1 Year Performance-72.03%-1.25%31.31%18.40%

Karyopharm Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KPTI
Karyopharm Therapeutics
3.7319 of 5 stars
$3.85
-5.4%
$37.40
+871.4%
-72.3%$35.16M$145.24M-0.29380Analyst Downgrade
LIMN
Liminatus Pharma
N/A$6.33
-4.8%
N/AN/A$164.68MN/A0.00N/AGap Up
INKT
MiNK Therapeutics
2.5494 of 5 stars
$40.61
-36.7%
$37.50
-7.7%
+121.4%$161.87MN/A-16.1230Analyst Downgrade
High Trading Volume
TIL
Instil Bio
3.156 of 5 stars
$24.49
flat
$119.00
+385.9%
+113.1%$160.65MN/A-2.05410Positive News
CRBU
Caribou Biosciences
2.6586 of 5 stars
$1.70
+4.3%
$8.50
+400.0%
-30.7%$158.11M$9.92M-1.05100News Coverage
Positive News
NXTC
NextCure
4.3702 of 5 stars
$4.90
+3.4%
$3.50
-28.6%
-75.7%$157.34MN/A-2.7890Analyst Forecast
High Trading Volume
IPHA
Innate Pharma
2.3347 of 5 stars
$1.70
-2.5%
$11.00
+547.1%
-18.0%$156.71M$21.77M0.00220News Coverage
Gap Up
LFVN
Lifevantage
4.2541 of 5 stars
$12.38
+3.1%
$30.50
+146.4%
+107.6%$155.86M$200.16M17.94260News Coverage
IMRX
Immuneering
3.4316 of 5 stars
$4.17
-5.7%
$13.25
+217.7%
+267.5%$150.06MN/A-2.1360Positive News
ENTA
Enanta Pharmaceuticals
3.7724 of 5 stars
$6.96
+6.1%
$18.00
+158.6%
-54.3%$148.81M$67.64M-1.53160Positive News
SPRO
Spero Therapeutics
3.9397 of 5 stars
$2.64
-6.0%
$5.00
+89.4%
+67.6%$147.60M$47.98M-2.06150Positive News

Related Companies and Tools


This page (NASDAQ:KPTI) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners